Abstract
The pyrimidine (uracil) analogue 3-oxauracil (OU) previously had been shown to completely inhibit the growth of E. coli B and decrease by 96% the replication of herpes simplex virus type 2 when present in the culture fluid at a concentration of 102 µM. Limited in vivo studies in mice demonstrated antiviral effects without significant toxicity when given i.p. daily for two weeks at a concentration of 3.23 mg/kg. However, the antineoplastic properties of OU were unknown. We assessed the ability of OU to inhibit the proliferation of various human tumor cell lines (3 pancreatic, 1 colon, 1 neuroendocrine, and 1 lung) in an in vitro radiometric (Bactec) system. In the pancreatic lines (RWP-2, MiaPaCa-2, and PANC-1), the colon line (HT-29), the neuroendocrine line (COLO 320DM), and the lung cancer cell line (SK-MES-1), OU at a concentration of 103 µM, produced a dramatic decrease in percent cell survival. When compared with cytotoxic drugs of choice for these tumor cells (gemcitabine, 5-fluorouracil, and adriamycin, respectively) a significantly higher concentration of OU was required usually to achieve comparable results with two exceptions. These were the HT-29 and the COLO 320DM cell lines. These results indicate OU has significant (p < 0.05) cytotoxic activity against pancreatic, colon, neuroendocrine, and nonsmall cell lung cancer lines, when compared to untreated control cultures. Additional in vivo testing of this potential antineoplastic agent is warranted.
Similar content being viewed by others
References
Skoda J, Flegelova Z, Farkas J: A new pyrimidine antimetabolite. Biochem Biophys Res Commun 50:80–83, 1973
Seal L, Jamison R: A simple method for typing clinical isolates of herpesvirus simplex: Replication in the presence of 2H-1,3 Oxazine-2,6 (3H)-Dione(Oxauracil). J Med Virol 6:21–27, 1980
Seal L, Jamison R: Evaluation of 2H-1,3 Oxazine-2,6(3H)-Dione (Oxauracil) in the treatment of herpesvirus simplex induced acute encephalitis in mice. J Med Virol 13:371–375, 1984
Stoychkov J, Mircheva J: Testing of 2,3-dihydro-1,3-6H-oxazine-dione (3-oxauracil) in mouse L1210 leukemia and 37 sarcoma. Cancer Treatment Reports 62:2121–2123, 1978
Vesela H, Vachova M, Elis J, Farkas J, Skoda J: Some cytostatic and pharmacological properties of 2,3-dihydro-1,3-6H-oxazine-2,6-dione (3-oxauracil). Neoplasma 25:413–421, 1978
Ujhazy V, Reiner P, Farkas J, Skoda J: Effect of 3-oxauracil (2,3-dihydro-1,3-6H-oxazine-dione) in L1210 leukemia. Neoplasma 24:259–261, 1977
Reiner P, Ujhazy V: Proliferation rate-drug sensitivity relation in clones isolated from heterogenic tumor cell population. Neoplasma 27:711–715, 1980
Reiner P, Mardiak J, Reinerova M, Ujhazy V: Inhibition of colony-forming cells from bone marrow of leukemic patients by 3-oxauracil. Neoplasma 28:533–539, 1981
Von Hoff D, Forseth B, Warfel L: Use of a radiometric system to screen for antineoplastic agents: Correlation with a human tumor cloning system. Cancer Res 45:4032–4038, 1985
Scheithauer W, Clark G, Moyer M, Von Hoff D: New screening system for selection of anticancer drugs for treatment of human colorectal cancer. Cancer Res 46:2703–2708, 1986
Arteaga CL, Forseth BJ, Clark GM, Von Hoff D: A radiometric method for evaluation of chemotherapy sensitivity: results of screening a panel of human breast cancer cell lines. Cancer Res 47:6248–6253, 1987
Kraemer HC, Thiemann S: How many subjects? In: Statistical Power Analysis in Research. Sage Publications, Newbury Park, CA, 1988, pp 101–112
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Seal, L., Von Hoff, D., Lawrence, R. et al. An in vitro assessment of the antineoplastic potential of 2H-1,3-Oxazine-2,6(3H)-dione (3-oxauracil), a novel pyrimidine. Invest New Drugs 15, 289–293 (1997). https://doi.org/10.1023/A:1005962224801
Issue Date:
DOI: https://doi.org/10.1023/A:1005962224801